Summary of Key Points from the Conference Call Industry Overview - The focus is on the Asia Pacific region, emphasizing competitive reinvention and corporate strategies to adapt to emerging technologies and multipolar supply chains [1][4][8]. Core Themes and Insights - Asia is undergoing significant transformation in growth and corporate strategies, with a focus on capital market reforms to enhance competitiveness [1][4]. - The updated Asia Thematic Focus List includes 25 stocks identified as conviction winners, projecting a three-year EPS CAGR of 16.1% for 2025-27, with a forward P/E of 22.6x and a PEG of 1.4x [7][8]. Sub-Thematic Analysis - **Top Sub-Themes**: - China's AI Path ranks highest, followed by the Diabesity Ecosystem and AI & Healthcare [7][8]. - The thematic fund flow and stock mapping have been deepened, quantifying and ranking growth, valuations, and performance across sub-themes [7][8]. Financial Metrics - The Asia Thematic Focus List is trading at a forward P/E of 22.6x and a PEG of 1.4x, indicating a robust growth outlook [7][8]. - Specific sub-themes show promising growth metrics: - **Critical Minerals**: 19.9% sales growth CAGR and 50.0% EPS growth [28]. - **Semiconductor Localization**: 23.2% sales growth CAGR and 32.2% EPS growth [30]. - **AI & Tech Diffusion**: 11.0% sales growth CAGR and 18.8% EPS growth [30]. Thematic Fund Flows - APAC-domiciled thematic funds' AUM reached $191 billion as of September 2025, with significant growth in "Robotics + Automation" and "Artificial Intelligence + Big Data" funds [20][22]. - Digital Economy thematic funds recorded the highest fund flows in Q3 2025 [25]. Valuation Insights - The report highlights that while some sub-themes exhibit strong revenue and EPS growth prospects, they also face high valuations [28]. - The **Future of Energy** sub-themes show lower growth outlooks but offer more valuation support [31]. Additional Observations - The report emphasizes the importance of understanding the competitive landscape and the need for companies to adapt to the evolving market dynamics in Asia [1][4]. - The analysis includes a ranking of sub-themes based on growth, valuation, and risk-reward profiles, providing a comprehensive view of investment opportunities [33][34]. Conclusion - The Asia Pacific region is positioned for significant growth driven by technological advancements and strategic reforms, with various sub-themes offering attractive investment opportunities despite varying valuation metrics [1][4][8].

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: China Healthcare, specifically in the Biotech sector within the Asia Pacific region [2][63]. Core Insights - **Next-Gen Immuno-Oncology (IO)**: This theme was prevalent throughout the discussions, with several large biopharma companies highlighting its significance in R&D. The consistency of data and overall survival benefits were noted as open questions [3][8]. - **China's R&D Advantages**: Companies emphasized China's rapid and efficient capabilities in conducting randomized controlled trials, particularly in therapeutic areas with less predictable preclinical models. This includes the ability to iterate through various modalities quickly [4][8]. - **Investor Inquiries**: Investors are primarily focused on two areas: 1. Due diligence on China's global narrative, particularly regarding companies' R&D strategies and opportunities in both China and global markets. 2. In-depth analysis of pipelines, with an emphasis on scientific quality and long-term R&D plans [5][8]. Additional Noteworthy Points - **Recognition of China's Role**: The importance of China in both commercial and R&D opportunities was acknowledged, although the extent of this recognition varies among overseas developers utilizing its infrastructure [8]. - **Morgan Stanley's Position**: The report indicates that Morgan Stanley maintains an attractive view of the China Healthcare industry, suggesting potential investment opportunities [6][63]. Conclusion The conference highlighted the growing significance of next-gen immuno-oncology therapies and China's pivotal role in the global biotech landscape, particularly in R&D efficiency and opportunities for investment. Investors are keenly interested in understanding the strategic positioning of companies within this dynamic environment.

Overall Performance - The second quarter of 2025 shows signs of recovery in the Chinese stock market, with A-shares stabilizing and MSCI China improving [2][3] - As of July 21, 2025, 1,528 A-share companies (30% of total, 25% of total market capitalization) issued earnings forecasts, with a net negative warning rate of -4.8%, an improvement from -18.8% in the previous quarter [2] - The MSCI China index, covering overseas-listed Chinese core assets, reported a net positive warning rate of +6.8%, the highest in four quarters, indicating a rebound in confidence from overseas investors [3] Sector Performance - Strong sectors include financial services, materials, and technology hardware, while consumer services, real estate, and software lag behind [5][6] - Financial services benefit from stable growth policies, materials see gains from commodity price recovery, and technology hardware thrives on innovation [5] - Real estate continues to face pressure due to inventory reduction and financing challenges, while consumer services are affected by slow recovery in domestic demand [5][6] Market Capitalization - Large-cap stocks show stability with a net negative warning rate of -1.4%, indicating strong risk resistance and high earnings certainty [7] - Small-cap stocks have significantly improved, with a net negative warning rate narrowing from -31.1% to -7.4%, reflecting recovery supported by policy and industry revival [7] - Mid-cap stocks perform moderately with a net negative warning rate of -12.7%, showing improvement but still lagging behind large-cap stocks [8] Earnings Forecast Adjustments - Sectors with upward adjustments include technology hardware, consumer staples, and pharmaceuticals, driven by increased orders and stable demand [9] - Sectors facing downward adjustments include semiconductors, utilities, consumer services, and real estate, reflecting cautious market sentiment [9] Investment Recommendations - Morgan Stanley identifies nine stocks to watch, primarily from materials, pharmaceuticals, and technology hardware sectors, based on positive earnings forecasts and analyst ratings [10][11] - Caution is advised for six stocks concentrated in real estate and certain consumer services, reflecting high earnings uncertainty [10][11] Future Outlook - The report suggests focusing on sectors benefiting from policy support, such as finance and infrastructure-related materials, as well as resilient consumer services and technology growth areas [12][13] - The overall recovery remains uneven, and investors are encouraged to prioritize quality stocks with stable earnings and reasonable valuations [13]

Investment Rating - The report maintains an Equal-weight (EW) stance on MSCI China within the global EM/APXJ framework [9]. Core Insights - The report anticipates higher near-term market volatility due to the US imposing additional tariffs on China, raising the total tariff rate to up to 65% [2][4]. - The A-share market is viewed as better positioned for hedging and diversification compared to the offshore market, as A-share investors are less sensitive to tariff changes [3]. - The direct impact on earnings from the tariffs is expected to be smaller than the overall drag on macroeconomic growth, with the MSCI China universe generating only 13% of its total revenue from markets outside China, and less than 3% from the US [7]. Summary by Sections Market Volatility - The report highlights that the recent tariff hikes could lead to elevated market volatility as the market adjusts to the potential economic impacts [2][4]. A-Share Market Positioning - The A-share market is recommended for investors seeking stability, as it has shown lower correlation with global markets and less volatility compared to offshore markets [3]. Earnings Impact - The report suggests that the overall drag on equity market earnings will be less severe than the impact on macro growth, primarily due to the limited revenue exposure of listed Chinese companies to the US market [7]. Companies with High US Revenue Exposure - A list of 30 companies with the highest revenue exposure to the US market is provided, indicating potential negative impacts on these companies in the near term [8]. Key Indicators to Monitor - The report advises monitoring the USDCNY exchange rate, signs of US-China negotiations, and any significant policy easing measures to stabilize domestic growth [9].

Summary of WuXi AppTec Co Ltd Conference Call Company Overview - **Company**: WuXi AppTec Co Ltd - **Industry**: Healthcare, specifically in the Asia Pacific region Key Financial Results - **2024 Revenue**: Rmb39.2 billion, a decrease of 2.7% year-over-year, but a growth of 5.2% year-over-year excluding Covid-related revenue [2][11] - **Adjusted Net Profit**: Rmb10.6 billion, down 2.5% year-over-year, with a record-high adjusted net profit margin (NPM) of 27.0% [2][11] - **4Q24 Performance**: Revenue of Rmb11.5 billion, an increase of 6.5% year-over-year, and adjusted net income of Rmb3.2 billion, up 27% year-over-year [2][11] Growth Drivers - **Key Growth Areas**: - Drug Manufacturing (D&M) revenue increased by 12% - Therapeutic Indications and Drug Evaluation Services (TIDEs) revenue surged by 70% - **Testing Services**: Remained weak, while Biology services showed a turnaround in 4Q24 [2][11] Guidance and Future Outlook - **2025 Revenue Guidance**: Expected growth of 10-15% in continuing operations, projecting revenue between Rmb41.5 billion and Rmb43 billion [3][10] - **Capital Expenditure**: Anticipated to rise to Rmb7-8 billion for global D&M capacity expansion, with free cash flow expected to remain healthy at Rmb4-5 billion [3][10] Shareholder Returns - **Dividends**: Declared a final dividend with a 30% payout and a special dividend of Rmb0.35 per share (~10% yield) [4] - **Share Buyback**: Announced a Rmb1 billion A-share buyback [4] Market Position and Valuation - **Stock Rating**: Overweight with a price target of HK$74.30, representing a 14% upside from the closing price of HK$65.45 on March 17, 2025 [7] - **Market Capitalization**: Approximately Rmb185.4 billion [7] Risks and Considerations - **Upside Risks**: Potential inflection of Fed rates leading to increased biotech funding, favorable government policies, and margin expansion through operational efficiency [16] - **Downside Risks**: Talent turnover, margin pressure from US operations, global competition, and geopolitical risks [16] Conclusion - The results and guidance from WuXi AppTec reinforce a strong fundamental outlook, with significant growth potential driven by a robust backlog and strategic capacity expansions [10]